Eli Lilly and Co / LLY

Equity | Generated Sep 15, 2026 11:31 PM EDT

Current price	Daily move	Bid / Ask	Previous close
$1,138.88	**+0.60 +0.05%**	**$1,137.00/$1,140.03**	**$1,138.28**

Market	**NYSE**
Industry	**Pharmaceuticals**
Market data as of	**Sep 15, 2026 11:31 PM EDT**

JW Intelligence Report

Complete | 3 of 3 sections | Sep 15, 2026 7:50 PM EDT

JW Rank	Rank label	Confidence	IV percentile
59.3 / 100	**Balanced**	**high**	**25 / 100**

Model reference	Upside scenario	Risk reference	Wheel strategy fit
$1,130.00	**$1,190.00**	**$1,105.00**	**71 / 100**

Options stance	**bullish**
Tail-risk safety	**56 / 100**
JW Rank data coverage / as of	**100.0% | Sep 15, 2026 7:50 PM EDT**

Key insight

LLY Option Market Implies Upside Potential Despite Recent Pullback

Market read

The LLY option market suggests bullish sentiment despite a recent pullback in the underlying stock price. While implied volatility is elevated, it's not unusually high for a company with LLY's growth prospects and upcoming catalysts like EASD data and Q3 earnings. The term structure shows backwardation, indicating traders expect near-term volatility to subside, potentially setting up for upside moves. The positive news flow from analyst upgrades and pipeline advancements further supports the bullish outlook.

Strategy context

LLY options offer opportunities for bullish strategies as the stock appears poised for a rebound. Traders can consider buying calls or call spreads, especially if the $1,100-$1,120 support holds.

JW AI conclusions

Short- and medium-term model interpretation

AI context bias	**Bullish**
AI analysis updated	**Sep 15, 2026 2:02 PM EDT**

Short-term scenario

Cautious buy on dip or hold for potential rebound over 1-3 weeks, driven by analyst upgrade and upcoming EASD data as catalysts; however, short-term technicals remain mixed with negative MACD and price below key short-term MAs. High uncertainty from recent 8%+ monthly pullback, possible continuation of weakness, and market volatility. Better entry on hold above $1,120 or dip to support.

Three-month outlook

Constructive to bullish over three months given GLP-1 market dominance, Foundayo oral launch traction, positive pipeline data (retatrutide, others), acquisitions expanding into mental health and autoimmune, raised 2026 guidance, and manufacturing investments. Analyst targets suggest 15-40% upside potential. Significant uncertainty remains due to elevated valuation (PE ~38), intensifying competition, potential pricing/reimbursement pressures, execution risks on new products, Q3 earnings on Oct 29, and broader market conditions. Positive EASD data or continued volume growth could drive toward $1,250-$1,400; negative surprises or sentiment shift could retest $1,100 or lower. Outcomes highly dependent on clinical/commercial execution and external factors.

Market sentiment

Recent posts focus positively on the Berenberg upgrade and potential rebound, with traders highlighting support around $1,100-$1,121 and a possible bull flag pattern. Some discussion of pipeline and GLP-1 leadership. Mixed with older concerns over high valuation, institutional ownership, and recent weakness. Spam posts promoting trading groups. Overall cautiously optimistic on news flow but acknowledging pullback and risks.

Supporting evidence

Berenberg upgraded LLY to Buy with a price target of $1,400 citing strong growth drivers like weight-loss drugs and Foundayo's success. | Positive comments from Morgan Stanley healthcare conference reinforce confidence in LLY's future. | The option market exhibits backwardation, suggesting traders anticipate near-term volatility to decrease. | Elevated implied volatility is not unusual for a company with LLY's growth potential and upcoming catalysts.

Risk watch

Recent pullback of over 8% in August raises concerns about potential continuation of weakness. | High valuation (TTM PE ~38) and intensifying competition pose risks to future growth. | Potential pricing/reimbursement pressures on new products could impact profitability.

Enhanced price structure

45 trading days with volume, model levels and current technical reference bands



45 complete trading-session observations

JW Rank factors

Score, source coverage and interpretation for each decision factor

JW RANK FACTOR PROFILE	COVERAGE	0 — 50 — 100
Liquidity	100.0%	83.7
Strategy Fit	100.0%	70.7
Technical Trend	100.0%	45.6
Market Tail Risk	100.0%	56.3
Fundamental Quality	100.0%	84.2
Volatility Pressure	100.0%	45.8

Decision summary

Primary model reads before the detailed indicator appendix

Momentum	Institutional flow	Structure	Volatility
bullish_recovery	**Below MVWAP**	**Above 200D trend**	**medium**

Decision indicators

Detailed momentum, institutional and structural observations

Momentum kinematics

Direction, velocity and oscillator state

Current read	**BULLISH RECOVERY | neutral | MACD decelerating**
Trend signal	**BULLISH RECOVERY**
RSI signal	**neutral**
RSI (7 / 14 / 21)	**40.03 / 41.98 / 45.16**
RSI velocity	**1.73**
MACD line / signal / histogram	**-17.79 / - / -11.92**
MACD acceleration	**-0.45**
Stochastic K / D	**12.24 / 8.31**

Institutional footprints

Volume-weighted cost, price location and flow

Current read	**Below institutional MVWAP | Distribution bias**
Institutional flow	**-2.14**
20-day MVWAP	**$1,189.61**
Price vs 20-day MVWAP	**-4.26%**
Daily reference VWAP	**$1,142.90**
Price vs daily reference	**-0.35%**
Volume	**774.83K**

Structural context

Long-term trend and volatility boundaries

Current read	**Above 200-day trend | Negative macro velocity**
Macro velocity	**-3.04**
20-day / 200-day SMA	**$1,178.68 / $1,065.32**
Bollinger range	**$1,076.64 - $1,280.71**
Bollinger position	**0.291**

Options and volatility intelligence

Structure, premium conditions and principal risks

IV rank	IV percentile	VVIX	SKEW
26 / 100	29 / 100	96.21	152.09

Market regime	**Calm**
Tail-risk regime	**NORMAL TAIL RISK**
Term structure	**backwardation**
Term slope	**-2.50 pts**
Skew read	**balanced**
Liquidity / quote coverage	**100.0%**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 15, 2026 2:52 PM EDT**
Options data quality	**Coverage 88.9%**

Option term structure

ATM implied-volatility curve by days to expiration



EXPIRATION	DTE	ATM IV	STATE
2026-09-18	3	35.6%	-
2026-09-25	10	32.9%	-
2026-10-02	17	33.1%	-

Reference spread payoff

Illustrative expiry profit/loss per one-lot structure, including quoted net credit

Bear Call Spread reference

Short $1,165.00 | Long $1,170.00 | Width $5.00 | Net credit $0.70



Max profit $70.00 | Max loss -$430.00 | Break-even $1,165.70 | Per contract at expiry

Event and tail-risk context

Known event windows and broad volatility conditions

Next earnings date	**2026-10-29**
Earnings IV-crush risk	**NOT MEASURED**
VIX	**17.58**
VVIX	**96.21**
SKEW index	**152.09**
Observation confidence	**high**
Option quote quality	**reliable**
Contracts observed	**89**
Contracts with quotes	**89**

Strategy fit

Generalized structure fit; not a personalized recommendation

Market structure

The LLY option market suggests bullish sentiment despite a recent pullback in the underlying stock price. While implied volatility is elevated, it's not unusually high for a company with LLY's growth prospects and upcoming catalysts like EASD data and Q3 earnings. The term structure shows backwardation, indicating traders expect near-term volatility to subside, potentially setting up for upside moves. The positive news flow from analyst upgrades and pipeline advancements further supports the bullish outlook.

Options context

LLY Option Market Implies Upside Potential Despite Recent Pullback

Wheel context

LLY options offer opportunities for bullish strategies as the stock appears poised for a rebound. Traders can consider buying calls or call spreads, especially if the $1,100-$1,120 support holds.

Observed evidence

Berenberg upgraded LLY to Buy with a price target of $1,400 citing strong growth drivers like weight-loss drugs and Foundayo's success. | Positive comments from Morgan Stanley healthcare conference reinforce confidence in LLY's future. | The option market exhibits backwardation, suggesting traders anticipate near-term volatility to decrease. | Elevated implied volatility is not unusual for a company with LLY's growth potential and upcoming catalysts.

Principal risks to monitor

Recent pullback of over 8% in August raises concerns about potential continuation of weakness. | High valuation (TTM PE ~38) and intensifying competition pose risks to future growth. | Potential pricing/reimbursement pressures on new products could impact profitability.

Fundamentals and events

Business quality, valuation and upcoming event context

Market capitalization **$1.07T**	P/E (TTM) **39.90**
ROE **92.6%**	Revenue growth **31.7%**
EPS growth **49.3%**	Operating margin **42.2%**
Net profit margin **33.5%**	Gross margin **-**
Free cash flow CAGR **5.9%**	Debt / equity **1.60**
Dividend yield **0.8%**	Beta **0.43**
52-week range **$712.05 - $1,292.65**	

Company or fund profile

Issuer identity and classification

Name **Eli Lilly and Co**	Market **NYSE**
Industry **Pharmaceuticals**	Country **US**
Currency **USD**	IPO date **1970-07-09**
Shares outstanding **941.74M**	52-week return **50.7%**
Book value per share **$35.98**	Revenue per share **$89.14**

Website	**lilly.com**

Latest strategy observation

Most recent shared general market signal available when this report was generated

LLY Covered Call signal

Sep 15, 2026 1:21 PM EDT

Covered Call | 2026-09-25

At signal $1,142.00 | Current $1,138.88

SHORT **Option $1,140.00 B $25.95 / A $29.10**

High turnover | CR $27.53

Complete technical details

Full supporting indicator set used by the symbol detail experience

Volatility and options market

Price movement and premium conditions

ATR	**$32.06**
ATR as % of price	**2.8%**
Volatility environment	**medium**
Current IV	**32.0%**
IV rank	**23 / 100**
IV percentile	**25 / 100**
Technical Snapshot IV source	**Private fundamentals snapshot**
Technical Snapshot IV observed at	**Sep 15, 2026 3:50 PM EDT**

Technical health and risk radar

Derived indicator health and event context

Overall health	**76 / 100**
Trend health	**78 / 100**
Momentum health	**77 / 100**
Volatility health	**68 / 100**
Structure health	**79 / 100**
Earnings risk / date	**low | 2026-10-29**
Macro risk	**unknown**
Volatility risk	**medium**
Structure risk	**low**

Structural indicator levels

Moving averages, volatility bands and observed trading ranges

SMA (20 / 50 / 200)	**$1,178.68 / $1,181.86 / $1,065.32**
EMA (9 / 21)	**$1,140.31 / $1,160.62**
Bollinger upper / middle / lower	**$1,280.71 / $1,178.68 / $1,076.64**

Structural indicator levels (continued)

Moving averages, volatility bands and observed trading ranges

FIELD	VALUE
Bollinger %B	**0.291**
True high / low	**$1,161.00 / $1,131.59**
5-day true high / low	**$1,161.00 / $1,113.29**

Three-day indicator history

Short-horizon change and the underlying three-session observations

INDICATOR	3-DAY CHANGE	SESSION 1 / 2 / 3
SMA20	-3.037	**-**
SMA50	-1.438	**-**
MVWAP20	-2.141	**-**
MACD	-0.453	**-**
RSI	1.735	**-**
Volume	-48597.330	**-**
ATR	-0.264	**-**
T1	-	**-18.12 / 1190.90 / 1153.95 / 1115.70**
T2	-	**-18.51 / 1192.73 / 1131.44 / 1113.29**
T3	-	**-16.43 / 1196.03 / 1133.79 / 1120.52**

Detailed options evidence

Supporting option-chain, execution and data-quality observations

Underlying price at observation	**$1,136.96**
Options Snapshot IV sources	**ATM: option chain | Rank/percentile: fundamentals**
Options Snapshot IV observed at	**Sep 15, 2026 2:52 PM EDT**
Options data coverage	**88.9%**
SKEW regime	**HIGH TAIL RISK SKEW**
VVIX regime	**VVIX RISING**
Front expiration / DTE	**2026-09-18 | 3 DTE**
Front at-the-money IV	**35.6%**
25-delta skew	**0.24**
Put / Call 25-delta	**$1,115.00 Delta -0.266 / $1,165.00 Delta 0.239**
Median option bid/ask spread	**17.1%**
Bid/ask spread	**-**
Contracts observed / quoted	**89 / 89**

Price context

Last Price: 1,136.96 | Bid: 1,136.69 | Ask: 1,137.22 | Previous Close: 1,138.28 | Change: -1.32 | Daily change: -0.12% | Update Time: 2026-09-15T14:52:05.110828-04:00 | Latest History Date: 2026-09-15 | Latest History Price: 1,136.96

Historical context

Trading-day sample: 60 sessions | First Date: 2026-06-22 | Latest Date: 2026-09-15 | Latest Price: 1,136.96 | Max Drawdown 60d Percent: -12.86%

Fundamental context

Current Iv Percent: 32.61% | Iv Rank: 26.21 | Iv Percentile: 29.48 | Next Earnings Date: 2026-10-29 | Ex Dividend Date: 2026-08-13

Important disclosures

Scope, limitations, risk and permitted interpretation

General market information only

This report is general quantitative research and market commentary. It is not investment, legal, tax or accounting advice; it is not an offer, solicitation, order, recommendation or promise of performance. It does not consider any reader's holdings, objectives, financial circumstances, risk tolerance or suitability.

Model observations - not instructions

JW Rank, strategy fit, model reference, upside scenario and risk reference levels are model observations. They are not entries, price targets, stops, position sizes or instructions to buy, sell, open, close or hold a security or option. A higher score does not imply lower risk or a guaranteed favorable outcome.

Data, AI and model limitations

Prices, volumes, fundamentals, options data, news-derived context and model outputs reflect the timestamps shown and may be delayed, incomplete, revised or inaccurate. AI-generated explanations can omit context or produce errors. Models can fail when volatility, liquidity, correlations or market regimes change.

Performance and scenario limitations

Past, hypothetical, back-tested, simulated and model-derived results are not indicative of future results. Strategy statistics may exclude commissions, fees, taxes, slippage, early assignment, execution constraints and other costs unless expressly stated. Actual outcomes may differ materially.

Options risk

Options are complex and are not suitable for all investors. They may involve total or substantial loss, assignment, early exercise, margin calls, liquidity and spread risk, volatility and Greek exposure, event risk, regime shifts and expiration risk. Multi-leg positions may not execute or close at modeled prices.

Investor responsibility and ODD

Use current market information, assess suitability independently and consult qualified professionals when appropriate. Before trading listed options, read Characteristics and Risks of Standardized Options (ODD) available from the Options Clearing Corporation at theocc.com.

Reference documents

Official product terms and standardized options disclosure

Jason Wheel	**jasonwheel.com**
Terms of Use	**jasonwheel.com / Terms**
Privacy Policy	**jasonwheel.com / Privacy**
Options Disclosure Document	**theocc.com / Options Disclosure Document**